1型糖尿病患者尿液代谢物谱与糖尿病肾病进展风险
这项前瞻性观察研究纳入2670例1型糖尿病患者,采用NMR代谢组学检测24小时尿液中51种代谢物,随访9.0±5.0年。调整基线白蛋白尿和CKD分期后,7种尿液代谢物与糖尿病肾病总体进展相关,其中2-羟基异丁酸还与新发白蛋白尿进展相关,6种氨基酸和焦谷氨酸与大量白蛋白尿进展相关。
要点
- 支链氨基酸(亮氨酸、缬氨酸、异亮氨酸)与糖尿病肾病总体进展独立相关。
- 2-羟基异丁酸与总体进展及正常白蛋白尿进展均相关。
- 尿液代谢组学可在大规模队列中分析,为肾病进展提供新标志物。
核心结论
- 支链氨基酸及其他尿液代谢物在基线白蛋白尿和CKD分期之上与糖尿病肾病进展相关。
- 总体进展与正常白蛋白尿、大量白蛋白尿进展的代谢物关联存在差异。
研究设计与样本
- 前瞻性观察性研究,纳入芬兰糖尿病肾病研究中2670例1型糖尿病患者。
- 收集24小时尿液,采用NMR代谢组学检测51种代谢物。
- 随访9.0±5.0年,终点为糖尿病肾病进展、终末期肾病或研究结束。
- Cox回归分析分别在全人群、1999例基线正常白蛋白尿者和347例基线大量白蛋白尿者中进行。
主要发现
- 调整基线白蛋白尿和CKD分期后,7种尿液代谢物与总体进展相关(p < 8 × 10-4)。
- 亮氨酸每1-SD肌酐标化代谢物浓度HR 1.47(95%CI 1.30, 1.66)。
- 缬氨酸HR 1.38(95%CI 1.22, 1.56),异亮氨酸HR 1.33(95%CI 1.18, 1.50)。
- 假尿苷HR 1.25(95%CI 1.11, 1.42),苏氨酸HR 1.27(95%CI 1.11, 1.46),柠檬酸HR 0.84(95%CI 0.75, 0.93)。
- 2-羟基异丁酸与总体进展相关(HR 1.30 [95%CI 1.16, 1.45]),也与正常白蛋白尿进展相关(HR 1.56 [95%CI 1.25, 1.95])。
关键数值与推荐
- 总体进展关联的显著性阈值为p < 8 × 10-4。
- 效应量以每1-SD肌酐标化代谢物浓度的HR表示。
临床怎么用
- 尿液代谢物谱可能辅助识别1型糖尿病肾病进展高风险患者。
- 2-羟基异丁酸或可用于正常白蛋白尿阶段的风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This prospective, observational study examines associations between 51 urinary metabolites and risk of progression of diabetic nephropathy in individuals with type 1 diabetes by employing an automated NMR metabolomics technique suitable for large-scale urine sample collections. METHODS: We collected 24-h urine samples for 2670 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy study and measured metabolite concentrations by NMR. Individuals were followed up for 9.0 ± 5.0 years until their first sign of progression of diabetic nephropathy, end-stage kidney disease or study end. Cox regressions were performed on the entire study population (overall progression), on 1999 individuals with normoalbuminuria and 347 individuals with macroalbuminuria at baseline. RESULTS: Seven urinary metabolites were associated with overall progression after adjustment for baseline albuminuria and chronic kidney disease stage (p < 8 × 10-4): leucine (HR 1.47 [95% CI 1.30, 1.66] per 1-SD creatinine-scaled metabolite concentration), valine (1.38 [1.22, 1.56]), isoleucine (1.33 [1.18, 1.50]), pseudouridine (1.25 [1.11, 1.42]), threonine (1.27 [1.11, 1.46]) and citrate (0.84 [0.75, 0.93]). 2-Hydroxyisobutyrate was associated with overall progression (1.30 [1.16, 1.45]) and also progression from normoalbuminuria (1.56 [1.25, 1.95]). Six amino acids and pyroglutamate were associated with progression from macroalbuminuria. CONCLUSIONS/INTERPRETATION: Branched-chain amino acids and other urinary metabolites were associated with the progression of diabetic nephropathy on top of baseline albuminuria and chronic kidney disease. We found differences in associations for overall progression and progression from normo- and macroalbuminuria. These novel discoveries illustrate the utility of analysing urinary metabolites in entire population cohorts.
引用
- Mutter S, Valo E, Aittomäki V, et al. Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes. Diabetologia. 2021. PMID: 34686904. doi:10.1007/s00125-021-05584-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。